Data amnesty status for follow-up forms ends April 1; retrospective forms due July 1
Effective April 1, 2021, all required living donor follow-up (LDF), organ specific transplant recipient follow-up (TRF), and recipient malignancy (PTM) forms will resume their expected submission dates as indicated in policy and will no longer be placed in “amnesty” status.
Beginning April 1, forms that had been placed in amnesty status between March 13, 2020, and March 31, 2021 will be reset to their original expected date. Transplant hospitals are responsible for completing these forms by July 1, 2021.
This decision was made as part of OPTN Executive Committee action on March 1, 2021, to approve the proposal “Conclude Relaxation of Data Submission Requirements for Follow-up Forms.”
All LDF, TRF, and PTM forms with an expected due date between March 13, 2020, and March 31, 2021, that are not yet validated, will appear in the Expected Data Section of TIEDI® as records that are due.
The deadline, listed in red for each form, will align with the original expected date of the form. Find more details here.
SRTR announces monitoring changes for July 2021 reports in response to COVID-19
The semi-annual transplant program-specific reports (PSRs) and organ procurement organization (OPO)-specific reports (OSRs) published by the Scientific Registry of Transplant Recipients will be adjusted for the July 2021 reporting cycle. The SRTR will implement the following:
- Post-transplant outcomes (including 1-month, 1-year, and 3-year graft and patient survival): Evaluation cohorts will continue to exclude transplants and follow-up time beyond March 12, 2020.
- Waitlist mortality rate: Evaluation cohorts will be modified on an organ-specific basis.
- Transplant rate: The first quarter following declaration of a national emergency will be excluded from the transplant rate evaluations for all organ types.
- Overall rate of mortality after listing: Patient follow-up will continue to be truncated on 3/12/2020.
- Offer acceptance rate: These evaluations will return to normal reporting cohorts.
- Eligible death conversion rate: Eligible deaths during the first quarter of the national emergency will be excluded from evaluation.
- Deceased donor organ yield: Deceased donors during the first quarter of the national emergency will be excluded from evaluation.
These changes were developed in coordination with the OPTN’s Membership and Professional Standards Committee. Find more details.
The latest information known for minimizing the risk of donor-derived COVID-19 transmission while maximizing donor utilization
The OPTN has released a Summary of Evidence on SARS-CoV-2 donor evaluation and testing, as well as organ recovery from donors with a history of COVID-19.
The document was compiled by the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC) in collaboration with colleagues representing AST, ASTS, AOPO, HRSA, and the CDC. It contains information on the following:
- SARS-CoV-2 deceased donor evaluation and testing
- Recovery of organs from deceased donors with a history of resolved COVID-19
- Recovery of organs from deceased donors with active COVID-19
- SARS-CoV-2 living donor testing and other precautions to minimize the risk of donor-derived COVID-19
- Recovery of organs from living donors with a history of resolved COVID-19
DTAC will review the document quarterly.
Lower respiratory tract testing: Resource lists tests authorized by the Food and Drug Administration to analyze lower respiratory tract specimens.
COVID-19 vaccination information for patients: VCU Health: COVID-19 vaccines and transplant patients—is vaccination safe?
New COVID-19 vaccination in heart and lung transplantation: Recommendations from the International Society of Heart & Lung Transplantation (ISHLT) COVID-19 Task Force
For COVID-19 related policy and operational questions, email email@example.com